At a glance
ClinicalIndex Comparison RecordN/ACompleted· 89 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study
In Brief
An observational study for Breast Cancer and Adenocarcinoma of Breast. Completed, enrolled 89 participants.
Detailed Summary
This study was a transnational pooled analysis of biological material from patients with resected high risk breast cancer who had received adjuvant chemotherapy with epirubicin and cyclophosphamide followed by weekly docetaxel or weekly paclitaxel.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Adenocarcinoma of Breast
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
Primary CompletionApr 2006
Study CompletionNov 2014
First PostedApr 2021
TodayJul 2026
First PostedApr 2, 2021
Enrollment StartFeb 1, 2004
Primary CompletionApr 1, 2006
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.3 years ago